SCHEMBL6767136

SCHEMBL6767136

CC(=O)Oc1c(C(C)C)cc(O)c(C=O)c1C(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.36
KDM4E B2RXH2 3/20 0.36
GAA P10253 3/20 0.36
ALDH1A1 P00352 3/20 0.36
THRB P10828 3/20 0.36
BLM P54132 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
MEN1 O00255 2/20 0.36
NPC1 O15118 2/20 0.36
USP2 O75604 2/20 0.36
LMNA P02545 2/20 0.36
POLB P06746 2/20 0.36
HPGD P15428 2/20 0.36
ALOX12 P18054 2/20 0.36
MAPK1 P28482 2/20 0.36
KMT2A Q03164 2/20 0.36
MCL1 Q07820 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
PKM P14618 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6764277 0.82 AKR1B1 (0.36) MAPTKDM4EGAAALDH1A1THRB
SCHEMBL6766773 0.82 MAPT (0.33) MAPTKDM4EGAAALDH1A1THRB
SCHEMBL9028778 0.78 AKR1B1 (0.38) MAPTKDM4EGAATHRBBLM
SCHEMBL9270934 0.74 FNTA (0.42) MAPTKDM4EALDH1A1BLMSMN1; SMN2
SCHEMBL5478950 0.74 AKR1B1 (0.50) MAPTKDM4EGAAALDH1A1THRB
SCHEMBL6766511 0.72 LDHA (0.33) MAPTKDM4EGAABLMSMN1; SMN2
SCHEMBL9028770 0.72 RXRA (0.35) MAPTKDM4EGAATHRBBLM
SCHEMBL6768274 0.72 PREP (0.42) MAPTKDM4EGAABLMSMN1; SMN2
SCHEMBL17935193 0.70 CA1 (0.46) BLMSMN1; SMN2PKMHTTCYP1A2
SCHEMBL4469962 0.70 CYP3A4 (0.39) MAPTKDM4EGAATHRBBLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6686389-B2 KIDNEY DISEASE, ORGAN TRANSPLANT CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2004-02-03 US disclosed
US-20020156296-A1 2,3-dihydrobenzofuran derivatives CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-10-24 US disclosed
US-6403639-B1 POTENT CYTOPROTECTIVE AGENT WHICH INHIBITS LIPID-PEROXIDATION FOR PREVENTION AND TREATMENT OF VARIOUS RENAL DISEASES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2002-06-11 US disclosed
EP-0995437-A1 2,3-DIHYDROBENZOFURAN DERIVATIVES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2000-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156296-A1 2,3-dihydrobenzofuran derivatives CBR1, CYP2F1, NDUFAF2 MAPT 4260/4885KDM4E 4048/4885GAA 1044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.